Please check the following:
- {{error.value}}
FREE membership
FREE membership
Join InvestSMART today
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
Please enter the 5 digit verification code sent to "{{user.DayPhone}}" Change number
We cannot send you a verification code via SMS to "{{user.DayPhone}}" Change number
{{ completedStep1 ? 'Start your free 15 day trial now' : content.trialHeading.replace('{0}', user.FirstName) }}
Please enter your mobile number and press send to receive a text message with a verification code.
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
Thank you
We have sent you an email with the details of your registration.
Purchase order
Sign up
OR
Sign up with
Login with
By continuing, you agree to our
Log in
Your account has been locked.
Please contact our {{ isPMAUser ? 'Portfolio Services' : 'Customer Service' }} Team:
- Call 1300 880 160
Looks you are already a member. Please enter your password to proceed
OR
Sign up with
Login with
By continuing, you agree to our
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Log in
Your account has been locked.
Please contact our {{ isPMAUser ? 'Portfolio Services' : 'Customer Service' }} Team:
- Call 1300 880 160
OR
Sign up with
Login with
By continuing, you agree to our
Upgrade Today
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
{{eventFunction.Name}}
{{eventFunction.EventTypeName}}
{{eventFunction.StartDate}}
{{eventFunction.EventTimings}}
{{eventFunction.VenueName}}
{{ t.Cost === 0 ? "FREE" : "$" + t.Cost.toFixed(2) }}
Quantity *
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
Check your inbox
- Verify your email address by clicking on the link we sent to {{user.Email}}
- You now have free access, we look forward to helping you on your financial journey.
TrivarX Ltd (ASX:TRI)
ALERT: Price-sensitive ASX Announcement for TRI
Current share price for TRI : $0.021 0.005 (31.25%)+
Announcement
Release
29 Apr 2026 8:29AM
Price at Release
$0.016
Full Release
Summary
On May 2, 2026, TrivarX Limited announced the appointment of Dr. Danielle Meyrick as the new CEO, effective from June 1, 2026. Dr. Meyrick brings over 20 years of extensive experience in clinical development, radiopharmaceuticals, and isotope-based technologies, having held senior leadership roles at notable companies like Telix Pharmaceuticals and ITM Isotopes Technologies. Her appointment is seen as a strategic move to advance TrivarX's Stabl-Im platform, which offers innovative diagnostic and imaging solutions for mental health and neuro-oncology. Under her leadership, the company plans to focus on clinical development and regulatory approval processes for the Stabl-Im platform, aiming for broad commercialisation. Dr. Meyrick's remuneration includes a base salary of $300,000 per annum and performance-based incentives with options and rights tied to specific developmental milestones. This appointment is a significant step for TrivarX as it transitions towards the commercialisation of its technology.
Key Points
- Dr Danielle Meyrick appointed as CEO effective 1 June 2026
- TrivarX Ltd focuses on the Stabl-Im platform for imaging solutions
- Dr Meyrick has over 20 years of experience in related fields
- Her previous roles include positions at Telix Pharmaceuticals and ITM Isotopes
- Stabl-Im utilizes stable isotope labelling for non-invasive imaging
- Dr Meyrick's remuneration includes $300,000 salary and performance incentives
- Company aims for clinical and regulatory advancements under her leadership
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
